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Research Article
A DNA-priming protein-boosting regimen significantly improves type 
1 immune response but not protective immunity to Trypanosoma cruzi 
infection in a highly susceptible mouse strain
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S H E I L A  S  K I N O S H I T A ,  A D R I A N A  E  F U J I M U R A  a n d  M A U R I C I O  M  R O D R I G U E S
Departamento de Microbiologia, Imunologia e Parasitologia, Centro de Terapia Gênica (Cintergen) Universidade 
Federal de São Paulo-Escola Paulista de Medicina, São Paulo, Brazil
Summary BALB/c or C57Bl/6 mice immunized with plasmids containing Trypanosoma cruzi genes developed
specific immune responses and protective immunity against lethal parasitic infection. In contrast, in the highly
susceptible mouse strain A/Sn, DNA vaccination reduced the peak parasitemia but promoted limited mouse survival
after challenge. In the present study, we tested whether the immunogenicity and protective efficacy of vaccination
could be improved by combining DNA and recombinant protein immunization regimens. A/Sn mice immunized
with plasmid p154/13 which harbours the gene encoding Trypanosoma cruzi trans-sialidase developed a predomi-
nant type 1 immune response. In contrast, immunization with the recombinant Trypanosoma cruzi trans-sialidase
protein adsorbed to alum generated a typical type 2 immune response. Simultaneous administration of both p154/13
and recombinant Trypanosoma cruzi trans-sialidase protein also led to a predominant type 2 immune response.
Sequential immunization consisting of two priming doses of p154/13 followed by booster injections with
recombinant Trypanosoma cruzi trans-sialidase protein significantly improved specific type 1 immune response, as
revealed by a drastic reduction of the serum IgG1/IgG2a ratio and by an increase in the in vitro interferon-gamma
secretion by CD4 T cells. Our observations confirm and extend previous data showing that a DNA-priming protein-
boosting regimen might be a general strategy to enhance type 1 immune response to DNA vaccines. Upon challenge
with Trypanosoma cruzi, no improvement in protective immunity was observed in mice immunized with the DNA-
priming protein-boosting regimen when compared to animals that received DNA only. Therefore, our results suggest
that in this experimental model there is no correlation between the magnitude of type 1 immune response and
protective immunity against Trypanosoma cruzi infection.
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Introduction
The obligatory intracellular protozoan parasite Trypanosoma
cruzi is the aetiologic agent of Chagas’ disease, a major health
problem for many Latin-American countries where the
disease afflicts more than 15 million individuals and causes
thousands of deaths every year. The poor prospect of treat-
ment raises the possibility that immune interventions, such as
immunization, could be useful as an additional strategy to
improve disease prevention and treatment efficacy.
Plasmids containing parasitic genes have been success-
fully used to elicit protective immunity against experimental
T. cruzi infection in BALB/c and C57Bl/6 mice.1–5 However,
in the highly susceptible mouse strain A/Sn, DNA vaccination
provided sufficient immunity to reduce the peak parasitemia
but failed to significantly improve mouse survival after
challenge.6
Here we report on an attempt to improve the immuno-
genicity and protective efficacy of DNA vaccination by
combining DNA and recombinant protein immunization regi-
mens. We selected for our studies a gene and the correspond-
ing recombinant protein representing the catalytic domain of
T. cruzi trans-sialidase (TS). They were chosen based on our
earlier observations that immunization of BALB/c mice with
a plasmid containing the gene encoding for the catalytic
domain of TS induced antibodies, CD4+ Th1, CD8+ Tc1 cells
and protective immunity against infection.1,5 In spite of the
high degree of protective immunity observed in DNA-
vaccinated BALB/c mice, this protective immunity could not
be duplicated in the highly susceptible mouse strain A/Sn.6
Based on these observations, we compared the antibody and
T-cell immune responses and, in some cases, protective immunity
against experimental infection in A/Sn mice immunized with:
1. a plasmid containing a gene encoding the catalytic domain
of TS
2. the recombinant TS protein adsorbed to alum
3. DNA and recombinant protein administered concomitantly
or
4. consecutively (DNA-priming protein-boosting regimen).
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Although we observed a significant increase in the type 1
immune response after the DNA-priming protein-boosting
regimen, upon challenge with T. cruzi, protective immunity in




Bloodstream trypomastigotes of the Y strain were obtained from
7 day-infected A/Sn mice. The blood was collected from the axillary
vein and transferred to a tube containing heparin. After centrifuga-
tion, the parasites were collected with plasma, centrifuged, and
washed twice in plain RPMI medium (Life Technologies, Rockville,
MD, USA). Female 5–8-week-old A/Sn mice used in this study were
purchased from the University of São Paulo.
Plasmid generation and purification
Commercially available plasmid pcDNA3 (Invitrogen, San Diego,
CA, USA) was used as expression vector. The plasmid denominated
p154/13 was created as described by Costa et al.1 Plasmids were
grown in Escherichia coli DH5α and purified on caesium chloride
density gradients according to a standard protocol.7 DNA concentra-
tion was estimated at 260 nm. DNA was diluted in PBS at a
concentration of 1 mg/mL and 50 µL was injected per leg.
Trans-sialidase purification
Recombinant TS protein was produced in E. coli as previously
described.8
Immunization and challenge
A/Sn mice were immunized according to a protocol described earlier.1
Briefly, both Tibialis anterioris muscles were injected with 3.5 µg of
cardiotoxin (Sigma, Saint Louis, MD, USA). Five days later, 50 µg
of plasmid DNA was injected i.m. at the same sites as those of
cardiotoxin injection (a total of 100 µg of plasmid per mouse). Each
mouse received i.m. three or four doses of 100 µg of plasmid DNA
injected at 0, 3, 5 and 7 weeks. Immunization with the recombinant
TS consisted of three or four i.p. doses of 20 µg protein adsorbed to
alum (Alhydrogel ‘85’-Superfos Biosector, Vedbaek, Denmark)
given at 0, 3, 5 and 7 weeks. Efficient coupling of recombinant TS to
alum was obtained by mixing 2.5 µL 2% (wt/vol) Al2O3 per µg of
recombinant protein for 2 h. Two weeks after immunization with the
plasmids and/or the recombinant protein, blood was collected from
the tail and the sera were analysed for the presence of antibodies to
TS. Three or five weeks after the last dose, mice were challenged
i.p. with 500 or 200 bloodstream trypomastigotes of the Y strain,
respectively. Parasite development was monitored in the blood
according to a standard method.9
Detection of antibodies to TS
Anti-TS antibodies were detected by ELISA as described by Costa
et al.1 Titres are reported as the reciprocal of the highest serum
dilution producing an average OD492 greater than 0.1. Enzyme-linked
immunosorbant assay for detection of subclasses of mouse IgG was
performed essentially as described above except that we used pools of
serum and the secondary antibodies were specific for mouse IgG1,
IgG2a and IgG2b (all obtained from ICN Biochemicals, Costa Mesa,
CA, USA) diluted 1 : 1000.
Cell-mediated immune response assays
A/Sn mice were immunized as described above. Two to four weeks
after the last immunization, cells were obtained from the spleens of
three animals. Red blood cells were lysed in the presence of 0.15 mol/L
NH4Cl, 1 mmol/L KHCO3 and 0.1 mmol/L EDTA, pH = 7.0. After
washing three times in plain RPMI 1640 medium, spleen cells were
resuspended in 1 mL of cell culture medium consisting of RPMI,
pH 7.4, supplemented with 2 mmol/L L-glutamine, 10 mmol/L
Hepes, 0.2% (wt/vol) sodium bicarbonate, 1% (v/v) non-essential
amino acid solution (all obtained from Life Technologies), 59 mg/L
of penicillin, 133 mg/L of streptomycin, 1 mmol/L sodium pyruvate,
5 × 10–5 mol/L 2-ME, and 2% (v/v) normal human AB serum (all
obtained from Sigma).
Cell viability was assessed using 0.2% (wt/vol) Trypan Blue
exclusion dye to discriminate between live and dead cells. Cell
concentration was estimated with the aid of a Neubauer chamber and
adjusted to 1.25 × 106 cells per mL in cell culture medium.
The cells were cultivated in flat-bottom 96-well plates (Corning,
Acton, MA, USA) in a final volume of 200 µL in triplicate. The rec.
protein was added to the cultures at final concentrations of 1 or
10 µg/mL. After 4 days, 0.5 µCi of [methyl-3H]-thymidine ([3H]-TdR,
Amersham) was added to each well. At the end of the incubation
period (18–20 h), lymphocytes were collected with the aid of a
semiautomatic cell harvester. The mitogen Concanavalin A (Sigma)
was always used as positive control of cell proliferation at a final
concentration of 2 µg/mL. Stimulation indexes (SI) were obtained by
dividing the counts per minute (cpm) of cultures with antigen by the
cpm of cultures containing medium only. The results were expressed
as the mean of triplicate cultures ± standard deviation of the mean
(SD).
For cytokine determination, 106 spleen cells were cultivated in
flat-bottom 96-well plates in a final volume of 200 µL in triplicate.
The rec. protein was added to the cultures at a final concentration of
1 or 10 µg/mL. Purified anti-CD4 (Gk1.5) and anti-CD8 (clone 2.43)
antibodies were added at a final concentration of 10 µg/mL. The
mitogen Concanavalin A was always used as positive control for
IFN-γ secretion at a final concentration of 2 µg/mL. After 5 days, the
supernatants were collected for cytokine determination.
Cytokine concentration was estimated by capture ELISA using
antibodies and recombinant cytokines purchased from PharMingen
(San Diego, CA, USA) exactly as described previously.10 The super-
natants were diluted twice or up to 10 times for a precise estimate of
cytokine concentration. Cytokine concentration in each sample was
determined from standard curves performed in parallel with known
concentrations of recombinant mouse IFN-γ. The detection limit of
the assays was 0.2 ng/mL. T-cell proliferation assays and cytokine
determinations were performed on three different occasions with
similar results.
Reverse trancriptase assisted polymerase chain reaction 
(RT-PCR)
For cytokine RT-PCR, 1.25 × 106 spleen cells were cultivated in
24-well plates in a final volume of 1 mL. The rec. protein was added
to the cultures at a final concentration of 10 µg/mL. Spleen cell RNA
was purified using TRIzol® (Life Technologies) according to the
manufacturer’s instructions. The RT-PCR was performed with 0.2 µg
of total RNA and 1 µmol/L of primers specific for the cDNA of the
housekeeping gene hypoxanthine-guanine phosphoribosyl transferase
(HPRT), and genes encoding type 2 cytokines IL-4, IL-5 and IL-10
using the One Step SuperScript RT-PCR System (Invitrogen). Specific
primers were kindly provided by Dr Moriya Tsuji, New York Uni-
versity School of Medicine.11 The number of cycles was determined
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experimentally for each cytokine cDNA. Polymerase chain reaction
were performed with a Perkin-Elmer 2400 GeneAmp PCR System.
Amplification products were electrophoresed in 1% (wt/vol) TAE
0.04M Tris-Acetate, 0.001M EDTA, pH = 8.0 agarose gels and
visualized by ethidium bromide staining and UV illumination. As
DNA size markers, we used λ HindIII fragments or 100 bp DNA
ladder (Life Technologies).
Statistical analysis
The one-way ANOVA and Tukey HSD tests available at the URL http:/
/faculty.vassar.edu/lowry/VassarStats.html were used to compare the
possible differences in the mean values.
Results
Initially, we compared the immune responses of A/Sn mice
immunized either with the TS plasmid p154/13 or the recom-
binant TS protein in alum, or both simultaneously. For that
purpose, groups of mice were immunized according to the
following protocols:
1. Mouse group 1: Three doses of pcDNA3 and alum admin-
istered i.m. and i.p., respectively
2. Mouse group 2: three doses of p154/13 and alum adminis-
tered i.m. and i.p., respectively
3. Mouse group 3: three doses of pcDNA3 and recombinant
TS protein in alum administered i.m. and i.p., respectively
4. Mouse group 4: three doses of p154/13 and recombinant
TS protein in alum administered i.m. and i.p., respectively.
As measured by ELISA, after three immunizing doses the
antibody levels to TS observed in mice immunized with the
recombinant TS and a control plasmid pcDNA3 (Table 1,
mouse group 3) were significantly higher (> 15-fold,
P < 0.01) than the titres observed in animals immunized with
p154/13 and alum (mouse group 2). Animals immunized
simultaneously with both p154/13 and the recombinant
protein (mouse group 4) displayed antibody titres to TS
similar to those observed in mice immunized with the recom-
binant protein alone (P > 0.05). The antibody kinetics did not
significantly vary between mouse groups 3 and 4 (data not
shown). Immunization with plasmid pcDNA3 and alum did
not elicit TS specific antibodies.
Next, we evaluated the subclasses of IgG elicited by immu-
nization with either p154/13 or the recombinant protein or both.
We found a marked difference in the pattern of antibody
response elicited by immunization with p154/13 (mouse group
2) when compared to the recombinant protein (mouse group 3
and 4). Mice immunized with plasmid p154/13 had an IgG1/
IgG2a ratio of 0.5 whereas animals immunized with the recom-
binant protein with or without p154/13 had a ratio several-fold
higher (63.09 and 31.62, respectively).
Subsequently, we evaluated T-cell proliferative responses
and IFN-γ secretion of spleen cells collected from these
animals. In repeated experiments, only spleen cells from mice
immunized simultaneously with both p154/13 and the recom-
binant protein (mouse group 4), displayed easily detectable
T cell proliferative responses (Fig. 1a). On the other hand,
only cells from mice immunized with p154/13 (mouse group 2)
secreted IFN-γ upon in vitro re-stimulation with the recom-
binant TS (Fig. 1b).
We concluded from these experiments that while immuni-
zation of A/Sn mice with plasmid p154/13 induced a type 1
immune response, immunization with the recombinant TS
protein alone or in the presence of p154/13 did not.
In the second part of our study, we compared the immune
responses of mice immunized with both p154/13 and the
recombinant TS protein administered simultaneously or
sequentially. For comparison purposes, we also used as
control animals immunized with p154/13 alone.
Groups of mice were immunized according to the follow-
ing protocols:
1. mouse group 1: four doses of pcDNA3 and alum adminis-
tered simultaneously i.m. and i.p., respectively
2. mouse group 2: four doses of p154/13 and recombinant TS
protein in alum administered simultaneously i.m. and i.p.,
respectively
3. mouse group 3: the first two doses consisted of p154/13
administered i.m., the third and fourth doses consisted of
recombinant TS protein in alum administered i.p.
4. mouse group 4: the first two doses consisted of p154/13
administered i.m., the third and fourth doses consisted of
p154/13 and recombinant TS protein in alum administered
simultaneously i.m. and i.p., respectively
5. mouse group 5: four doses of p154/13 administered i.m.
Table 1 Antibody titres and IgG subclasses of mice immunized with p154/13 or recombinant Trypanosoma cruzi trans-sialidase (TS) protein or
both
Mouse group Immunization* Antibody titres† IgG subclasses‡ Ratio 
IgG1/IgG2a(log) IgG1 IgG2a IgG2b
1 Alum + pcDNA3 < 2.00 ± 0.00 NT NT NT NT
2 Alum + p154/13 5.30 ± 0.20§ 5.00 5.30 5.00 0.50
3 Rec. TS/alum + pcDNA3 6.50 ± 0.20§ 6.80 5.00 5.30 63.09
4 Rec. TS/alum + p154/13 6.30 ± 0.30§ 7.10 5.60 5.60 31.62
* A/Sn mice were immunized as follows: Mouse group 1: Three doses of pcDNA3 and alum administered i.m. and i.p., respectively. Mouse
group 2: Three doses of p154/13 and alum administered i.m. and i.p., respectively. Mouse group 3: Three doses of pcDNA3 and recombinant TS
protein in alum administered i.m. and i.p., respectively. Mouse group 4: Three doses of p154/13 and recombinant TS protein in alum administered
i.m. and i.p., respectively. † Fourteen days after the third immunization, blood samples were collected and each individual serum sample was
assayed in serial dilutions for the presence of antibodies to recombinant TS by ELISA. Results represent the mean value obtained for six mice ±
standard deviation of the mean (SD). ‡ Results represent the mean value of triplicate samples of serum pools. § The results obtained for groups 2,
3 and 4 were compared by one-way ANOVA and Tukey HSD tests. The antibody titres of groups 3 and 4 were higher than the titres of group 2
(P < 0.01). The antibody titres of groups 3 and 4 were not different (P > 0.05). NT, not tested.
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As measured by ELISA, the antibody levels to TS
observed in mice of groups 2, 3 and 4 were similar. These
antibody titres were significantly higher (P < 0.01) than the
titres observed in animals immunized with p154/13 alone
(mouse group 5). Immunization with plasmid pcDNA3 and
alum did not elicit TS specific antibodies (Table 2).
The evaluation of the IgG subclasses elicited in the
different mouse groups showed a striking difference in the
pattern of antibody response elicited in mouse groups 3 or 4
when compared to mouse group 2. Mice immunized simulta-
neously with p154/13 and the recombinant TS protein (mouse
group 2) had an IgG1/IgG2a ratio of 251.2 whereas animals
immunized first with p154/13 and subsequently with the
recombinant protein with (mouse group 4) or without p154/13
(mouse group 3) had a ratio more than 100-fold lower (1.00
and 1.99, respectively).
During the evaluation of the T-cell proliferative responses
of spleen cells collected from these animals, we found that
cells from mice immunized with p154/13 and the recom-
binant protein (mouse groups 2, 3 and 4), displayed T-cell
proliferative responses upon in vitro re-stimulation with the
antigen (Fig. 2a). In contrast, cells from mice immunized with
p154/13 (mouse group 5) failed to proliferate in vitro. Cells
from control animals immunized with plasmid pcDNA3 and
alum also failed to proliferate in response to the antigen.
Interferon-γ secretion was evaluated after in vitro re-
stimulation of spleen cells with the recombinant TS protein.
Cells obtained from mice sequentially immunized with p154/13
and the recombinant protein (Fig. 2b, mouse groups 3 and 4)
secreted much higher levels of IFN-γ than cells from mice
injected with p154/13 alone (mouse group 5). In spite of the
T-cell proliferative response, in the supernantant of cells from
mice immunized simultaneously with p154/13 and the recom-
binant protein (mouse group 2); we could not detect the
presence of this cytokine. Cells from control animals immu-
nized with plasmid pcDNA3 and alum also did not secrete
IFN-γ in response to the antigen.
The T-cell proliferative response and IFN-γ secretion were
dependent on the activation of CD4+ T cells. When compared
to culture containing medium only, the presence of anti-CD4
MAb significantly inhibited the antigen-specific IFN-γ pro-
duction by spleen cells obtained from mice sequentially
immunized with p154/13 and the recombinant protein. In
contrast, the addition to the cultures of anti-CD8 MAb did not
reduce the IFN-γ secretion by these spleen cells (Table 3).
Similar results were observed if we used in culture either 10
or 1 µg/mL of recombinant antigen (data not shown).
In several opportunities, we were unable to detect the
presence of type 2 cytokines (IL-4, IL-5 and IL-10) in the
supernatants of in vitro re-stimulated spleen cells from immu-
nized mice. A possible explanation for that can be the fact that
these cytokines are consumed by activated T cells.12 To
determine whether these cytokines were being produced in
response to the in vitro antigenic stimulation, we used RT-PCR
which is a more sensitive technique. For that purpose, we
used as target for a semiquantitative RT-PCR, RNA purified
from spleen cells that had been in vitro re-stimulated or not
with the recombinant antigen.
As seen in Fig. 3, upon in vitro re-stimulation with recom-
binant TS, specific RT-PCR products were detected for IL-4
and IL-10 in the RNA of spleen cells from mice injected with
Figure 1 A/Sn mice were immunized as follows: Mouse group
1: Three doses of pcDNA3 and alum administered i.m. and i.p.,
respectively. Mouse group 2: Three doses of p154/13 and alum
administered i.m. and i.p., respectively. Mouse group 3: Three
doses of pcDNA3 and recombinant Trypanosoma cruzi trans-
sialidase (TS) protein in alum administered i.m. and i.p., respec-
tively. Mouse group 4: Three doses of p154/13 and recombinant
TS protein in alum administered i.m. and i.p., respectively. Three
weeks after the last immunization, pooled spleen cells were
collected from three immunized mice. Spleen cells were re-
stimulated in vitro with 1 or 10 µg/mL of recombinant TS protein.
(a) [3H]-TdR incorporation was estimated after 5 days in culture.
Results are expressed as average of stimulation indices (SI) of
triplicate cultures ± SD. , 1.0 µg/mL; , 10.0 µg/mL. (b) After
5 days in culture, the supernatants were collected and the concen-
tration of IFN-γ was estimated. The concentration of IFN-γ in
culture without antigen was below the detection limit of tech-
nique. Results are expressed as average of triplicate cultures ±
SD. , 1.0 µg/mL; , 10.0 µg/mL.
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p154/13 and recombinant TS protein (mouse groups 2, 3 and
4). Interleukin-5 transcripts were only detected in RNA from
spleen cells of mice immunized simultaneously with p154/13
and recombinant TS protein (mouse group 2). In contrast,
RNA purified from cells of mice immunized with p154/13
alone did not present detectable transcripts for any of the type
2 cytokines. In parallel experiments, we observed that IL-4,
IL-5 and IL-10 transcripts were also present in in vitro re-
stimulated spleen cells from mice immunized with recom-
binant TS in alum (data not shown).
We complemented our studies by comparing the capacity
of some of the different protocols of immunization in induc-
ing protective immunity against T. cruzi infection. For this
purpose, A/Sn mice were immunized according to the follow-
ing protocols:
1. mouse group 1: the first two doses consisted of pcDNA3
administered i.m., the third and fourth doses consisted of
pcDNA3 and alum administered simultaneously i.m. and
i.p., respectively
2. mouse group 2: four doses of recombinant TS protein in
alum administered i.p.
3. mouse group 3: four doses of p154/13 administered i.m.,
and
4. mouse group 4: The first two doses consisted of p154/13
administered i.m. The third and fourth doses consisted of
p154/13 and recombinant TS protein in alum administered
simultaneously i.m. and i.p., respectively.
The efficiency of the immunizations was confirmed by
estimating the antibody titres and subclasses of IgG before
challenge (Table 4). Immunized and control mice were chal-
lenged i.p. with 200 or 500 bloodstream trypomastigotes.
These doses represent, respectively, two or five times the
number of parasites required to cause death of 100% of the
mice.
We observed a significant reduction in the peak para-
sitemia of animals from mouse groups 2, 3 and 4 when
compared to control mice (P < 0.05, in all cases). The para-
sitemia of animals from mouse groups 3 and 4 was signifi-
cantly lower than the parasitemia of animals from mouse
group 2 (P < 0.05, in both cases). However, no difference was
detected in the parasitemia of mice from mouse groups 3 and
4 (P > 0.05). Similar results were obtained for animals chal-
lenged with 200 or 500 bloodstream trypomastigotes of
T. cruzi (Fig. 4a,c).
We also recorded the timing of mouse mortality among the
different mouse groups after the challenge with T. cruzi.
Control mice challenged with 200 or 500 parasites died
between 14 and 18 days of infection (Fig. 4b,d). Animals
from mouse group 2 did not survive much longer and most of
them died before day 18. Animals immunized with p154/13
(mouse group 3) survived significantly longer than control
mice after a challenge with 200 or 500 parasites (Fig. 4b,d).
Finally, we observed that animals vaccinated with p154/13
and recombinant TS protein (mouse group 4) survived signif-
icantly longer than control mice after a challenge dose of 200
trypomastigotes. However, this protocol of immunization did
not promote a significantly longer survival when compared to
animals immunized only with p154/13 (Fig. 4b). After chal-
lenged with a higher parasite dose, animals from mouse group
4 died sooner than animals immunized only with p154/13
(Fig. 4d).
Discussion
In the present study we characterized the immunogenicity and
protective efficacy against experimental T. cruzi infection of
combined DNA and recombinant protein immunization regi-
mens. Our experiments indicated that A/Sn mice immunized
only with p154/13 displayed a predominant type 1 immune
response. Immunization with the recombinant TS protein
alone or in the presence of p154/13 induced significantly
higher antibody titres and a typical type 2 immune response.
Sequential immunization with p154/13 followed by recom-
binant TS protein displayed mixed type 1 and 2 immune
responses. However, the most striking observation was the
fact that the magnitude of the type 1 immune response in
these mice was significantly higher than that observed in
animals immunized with p154/13 alone. Two priming doses




IgG subclasses‡ Ratio IgG1/IgG2a 
Mouse group 1st and 2nd doses 3rd and 4th doses IgG1 IgG2a IgG2b
1 Alum + pcDNA3 Alum + pcDNA3 < 2.00 ± 0.00 NT NT NT NT
2 Rec. TS/alum + p154/13 Rec. TS/alum + p154/13§ 7.60 ± 0.15 8.30 5.90 6.20 251.2
3 p154/13 Rec. TS/alum§ 7.15 ± 0.22 6.80 6.50 6.20 1.99
4 p154/13 Rec. TS/alum + p154/13§ 7.10 ± 0.18 6.50 6.50 5.90 1.00
5 p154/13 p154/13§ 5.65 ± 0.12 5.90 5.90 5.30 1.00
*A/Sn mice were immunized as follows: Mouse group 1: Four doses of pcDNA3 and alum administered simultaneously i.m. and i.p.,
respectively. Mouse group 2: Four doses of p154/13 and recombinant TS protein in alum administered simultaneously i.m. and i.p., respectively.
Mouse group 3: The first two doses consisted of p154/13 administered i.m. The third and fourth doses consisted of recombinant TS protein in alum
administered i.p. Mouse group 4: The first two doses consisted of p154/13 administered i.m. The third and fourth doses consisted of p154/13 and
recombinant TS protein in alum administered simultaneously i.m. and i.p., respectively. Mouse group 5: Four doses of p154/13 administered i.m.
† Fourteen days after the fourth immunization, blood samples were collected and each individual serum sample was assayed in serial dilutions for
the presence of antibodies to recombinant TS by ELISA. Results represent the mean value obtained for six mice ± SD. ‡ Results represent the mean
value of triplicate samples of serum pools. § The results obtained for groups of 2, 3, 4 and 5 were compared by one-way ANOVA and the Tukey HSD
test. The antibody titres of group 2 were higher than the titres of groups 3, 4 and 5 (P < 0.01). The antibody titres of groups 3 and 4 were higher than
the titres of group 5 (P < 0.01). The antibody titres of groups 3 and 4 were not different (P > 0.05). NT, not tested.
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with p154/13 followed by recombinant protein boosting
caused a dramatic change in the IgG1/IgG2a ratio and the
secretion of significantly higher amounts of IFN-γ by spleen
cells of immunized mice.
Essentially, our results obtained with the T. cruzi TS gene
priming-rec. T. cruzi trans-sialidase protein boosting immuni-
zation are compatible with recent reports which have explored
a similar strategy of immunization using genes/proteins
expressed in different pathogenic microorganisms such as
viruses and bacteria.13–19 DNA-priming protein-boosting
immunization takes advantage of the fact that DNA immuni-
zation has the ability to guide the immune responses toward a
type 1 response. The reason for such a bias toward a type 1
response is attributed to the immuno-modulatory capacity of
bacterial DNA. Unmethylated bacterial DNA contains CpG
oligonucleotides which are recognized by Toll-9 receptors.20
Upon recognition, dendritic and T cells are activated and
produce IL-12 and IFN-γ, as well as other pro-inflammatory
cytokines and chemokines which support the development of
type 1 immune responses.21,22
This type 1 immune response generated after priming with
DNA is subsequently boosted by injection of protein in
adjuvant, a fact that is not seen after subsequent immuniza-
tions with DNA. The precise reason why subsequent immuni-
zations with DNA failed to further expand type 1 immune
cells is unknown at present.
Altogether, the studies performed so far support the view
that the DNA-priming protein-boosting immunization might
represent a general strategy to improve antibody, CD4 type 1
and, in some cases, CD8 T cell immune responses against a
variety of microbial antigens. Although most of the studies
have been performed in the mouse model, a single study
performed with non-human primates (Rhesus monkeys)
demonstrated that this immunization regimen also improved
immune response in apes.13
In spite of the improvement of the type 1 immune response
observed after the DNA-priming protein-boosting regimen,
protective immunity against T. cruzi infection was similar to
that obtained in animals that received DNA only. The precise
reason for the lack of correlation between the magnitude of
type 1 immune response and protective immunity against
T. cruzi infection in this highly susceptible mouse strain is
unknown. However, we may speculate that the type 1
immune response alone may not be sufficient for an effective
protective immunity against infection.
The lack of protective immunity in A/Sn mice contrasts
with our earlier results showing that vaccination of BALB/c
mice with plasmid p154/13 generated sufficient immunity to
reduce the peak parasitemia and to abolish the mortality caused
by T. cruzi infection.1,5 A detailed characterization of the
immune responses generated by p154/13 in BALB/c mice
showed that these mice develop specific CD8 Tc1 cells in
addition to TS specific antibodies and CD4 Th1 cells.5,10 Also
relevant was our recent observation that the presence of a DNA
sequence encoding a CD8 T cell epitope is important for
efficient protective immunity induced by DNA vaccination.5
Similarly to vaccination with plasmid p154/13, it has been
well established that during the course of experimental infec-
tion CD4 and CD8 T cells complement each other to provide
optimal host resistance against infection. Genetically defi-
cient mice that do not express either CD4 or CD8 T-cells are
Figure 2 A/Sn mice were immunized as follows: Mouse group 1:
Four doses of pcDNA3 and alum administered simultaneously i.m.
and i.p., respectively. Mouse group 2: Four doses of p154/13 and
recombinant Trypanosoma cruzi trans-sialidase (TS) protein in alum
administered simultaneously i.m. and i.p., respectively. Mouse group
3: The first two doses consisted of p154/13 administered i.m. The
third and fourth doses consisted of recombinant TS protein in alum
administered i.p. Mouse group 4: The first two doses consisted of
p154/13 administered i.m. The third and fourth doses consisted of
p154/13 and recombinant TS protein in alum administered simultane-
ously i.m. and i.p., respectively. Mouse group 5: Four doses of p154/13
administered i.m. Two weeks after the last immunization, pooled
spleen cells were collected from three immunized mice. Spleen cells
were restimulated in vitro with 1 or 10 µg/mL of recombinant TS
protein. (a) [3H]-TdR incorporation was estimated after 5 days in
culture. Results are expressed as average of SI of triplicate cultures ±
SD. , 1.0 µg/mL; , 10.0 µg/mL. (b) After 5 days in culture, the
supernatants were collected and the concentration of IFN-γ was
estimated. The concentration of IFN-γ in culture without antigen was
below the detection limit of the technique. Results are expressed as
average of triplicate cultures ± SD. , 1.0 µg/mL; , 10.0 µg/mL.
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Table 3 CD4 T-cell dependence of T-cell proliferative response and IFN-γ secretion by spleen cells of mice immunized with p154/13 followed by
recombinant Trypanosoma cruzi trans-sialidase (TS) protein
Mouse 
group
1st and 2nd doses* 3rd and 4th doses* SI† in the presence of IFN-γ (ng/mL) secretion‡ in the presence of
recombinant TS protein and recombinant TS protein and
Medium anti-CD4 anti-CD8 Medium anti-CD4 anti-CD8
3 p154/13 Rec. TS/alum 21.5 ± 0.30 5.4 ± 0.6 22.10 ± 0.9 3.2 ± 0.70 < 0.2 4.5 ± 2.1
4 p154/13 Rec. TS/alum + p154/13 34.5 ± 1.40 6.8 ± 0.8 47.2 ± 0.48 6.0 ± 1.10 < 0.2 12.0 ± 2.8
* A/Sn mice were immunized as described in the legend of Table 2. † Three weeks after the last immunization, pooled spleen cells were
collected from three immunized mice and re-stimulated in vitro with 10 µg/mL of recombinant TS protein in the presence or absence of anti-CD4
and anti-CD8 MAb. [3H]-TdR incorporation was estimated after 5 days in culture. Results are expressed as average of SI of triplicate cultures ± SD.
‡ Three weeks after the last immunization, pooled spleen cells were collected from three immunized mice and re-stimulated in vitro with 1 µg/mL
of recombinant TS protein in the presence or absence of anti-CD4 and anti-CD8 MAb. After 5 days in culture, the supernatants were collected and
the concentration of IFN-γ was estimated. The concentration of IFN-γ in culture without antigen was below the detection limit of the technique.
Results are expressed as average of triplicate cultures ± SD.
Figure 3 Groups of A/Sn mice were immunized as described in the legend to Fig. 2. Three weeks after the last immunization, pooled
spleen cells were collected from three immunized mice. Ribonucleic acid was purified from spleen cells cultivated in the presence (+) or
absence (–) of recombinant Trypanosoma cruzi trans-sialidase (TS) protein (10 µg/mL). Reverse trancriptase assisted polymerase chain
reaction (RT-PCR) was performed using primers specific for the cDNA of the housekeeping gene hypoxanthine-guanine phosphoribosyl
transferase, or genes encoding type 2 cytokines IL-4, IL-5 and IL-10.
Table 4 Antibody titres and IgG subclasses of mice immunized with DNA and/or recombinant Trypanosoma cruzi trans-sialidase (TS) protein
before challenge with T. cruzi
Immunization* Antibody titres† (log) IgG subclasses‡ Ratio IgG1/IgG2a
Mouse groups 1st and 2nd doses 3rd and 4th doses IgG1 IgG2a IgG2b
1 pcDNA3 Alum + pcDNA3 < 2.00 ± 0.00 NT NT NT NT
2 Rec. TS/alum Rec. TS/alum 6.75 ± 0.12 § 6.80 5.00 5.00 63.09
3 p154/13 p154/13 5.00 ± 0.10 § 5.00 4.70 4.40 2.00
4 p154/13 Rmum + p15m 6.75 ± 0.12 § 6.50 6.20 6.20 2.00
* A/Sn mice were immunized as follows: Mouse group 1: The first two doses consisted of pcDNA3 administered i.m. The third and fourth doses
consisted of pcDNA3 and alum administered simultaneously i.m. and i.p., respectively. Mouse group 2: Four doses of recombinant TS protein in
alum administered i.p. Mouse group 3: Four doses of p154/13 administered i.m. Mouse group 4: The first two doses consisted of p154/13 adminis-
tered i.m. The third and fourth doses consisted of p154/13 and recombinant TS protein in alum administered simultaneously i.m. and i.p., respec-
tively. † Ten days after the fourth immunization, blood samples were collected and each individual serum sample was assayed in serial dilutions for
the presence of antibodies to recombinant TS by ELISA. Results represent the mean value obtained for 12 mice ± SD. ‡ Results represent the mean
value of triplicate samples of serum pools. § The results obtained for groups 2, 3 and 4 were compared by one-way ANOVA and Tukey HSD tests.
The antibody titres of groups 2 and 4 were not different (P > 0.05). The antibody titres of groups 2 and 4 were higher than the titres of group 3
(P < 0.01). NT, not tested.
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susceptible to infection when compared to wild type mice.23
MHC class I- or MHC class II-deficient mice were also
susceptible to infection, emphasizing that both T cell popula-
tions are important for the naturally acquired immunity
against infection (Tarleton et al.24 reviewed in Dos Reis).25
Based on these observations, we believe that it is plausible
to propose that the high mortality observed in A/Sn mice
immunized with p154/13 may occur due to the lack of specific
CD8 T cells. In order to overcome this problem, we are
currently characterizing other parasitic antigens which may
contain epitopes recognized by CD8 T cells from A/Sn mice.
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